- Genus, a global pioneer in animal genetics, has announced the first jury verdicts in its anti-trust litigation against Inguran LLC, operating as Sexing Technologies ('ST'), relating to ABS's Genus Sexed Semen processing technology.

At the trial, in the US District Court for the Western District of Wisconsin where the verdicts were announced yesterday, the jury found that ABS and Genus had proved that ST had wilfully maintained monopoly power in the market for sexed bovine semen processing in the US since July 2012.

The jury also found that Genus had not proved that it had suffered injury as a result of ST's wilful maintenance of monopoly power.

The jury has still to consider ST's counter claims related to two of its US patents (numbers 8,206,987 and 8,198,092) and ST's counter claims that Genus breached confidentiality obligations under the 2012 semen sorting agreement between the parties.

The jury is expected to deliver verdicts on these matters shortly. In addition the jury will also consider, if applicable, a verdict on damages in relation to these matters later this week.

GSS is a novel technology for sexing bovine semen that does not subject the sperm cells to high pressures and forces. Dairy farmers have a preference for female calves, and the use of gender skewed sexed semen in artificial insemination provides customers with female calves from ABS's elite genetic lines.

The commercial launch of GSS product would provide ABS customers and third party bull studs with an alternative service provider and increased competition in the market for the processing of sexed bovine semen.

Genus will update the market as further verdicts are announced and as post verdict motions are considered.

Story provided by